Oct 15: Drug maker Dr Reddy’s Laboratories Ltd on Monday announced receipt of approval for its Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules, in the United States market from the US Food and Drug Administration (USFDA). The company is working towards launching the product, it said.
The Aggrenox brand and generic had US sales of approximately $183 million MAT for the most recent twelve months ending in August 2018 according to IMS Health. Aggrenox is a registered trademark of Boehringer lngelheim.
Dr. Reddy’s Aspirin and Extended-Release Dipyridamole Capsules are available in 25 mg/200 mg strength with 60 count bottle size.